The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.

Whether you're hitting the pavement or getting your miles in on the treadmill, Brooks running gear is up for the challenge.

From a custom bourbon experience to Bold Picks by Eli Manning, here is what's happening on Kentucky's bourbon scene this ...

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares could remain under the microscope on Wednesday after falling sharply ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...

SAN FRANCISCO — Eli Lilly said Monday it would acquire a cancer program from startup Scorpion Therapeutics in a deal worth up to $2.5 billion, as the Indianapolis company broadens its pipeline.

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...